Search

The article explores the various modalities for the delivery of chemotherapy for retinoblastoma in children. These treatment modalities include intravitreal, intravenous (IV), and intra-arterial. It notes that chemotherapy for children with retinoblastoma demonstrate good responses using six cycles of three chemoreductive agents including vincristine, etoposide, and carboplatin. Moreover, Sub-Tenon's chemotheraphy is used with chemoreduction for advanced cases of retinoblastoma.

The article discusses research which found that consolidation docetaxel after treatment with cisplatin, etoposide and concurrent chest radiation did not improve survival in lung cancer. It references a study published in a 2008 issue of the "Journal of Clinical Oncology." It was found that 28.8 percent of patients in the docetaxel group were hospitalized during the treatment compared to 8.1 percent of patients in the observation arm. The researchers also noted that 5.5 percent of patients died as a result of docetaxel.

The article reports on the findings of a study which revealed the link between radiation-related pneumonitis and >20 Gy radiation. Patients who participated in the study were treated with cisplatin etoposide plus Gy thoracic radiation docetaxel. Some were also assigned with maintenance therapy of gefitinib or placebo.

The article discusses research being done on the efficacy of topotecan. It references a study published in a 2008 issue of the "Journal of Clinical Oncology." It has been found that topotecan plus oral etoposide and topotecan plus gemcitabine were no more effective than topotecan alone. The research team also observed that platinum-sensitive patients survived significantly longer than platinum-resistant patients.

The article discusses a research from Germany on the efficacy of bleomycin, etoposide and cisplatin chemotherapy for treating stage 1 nonseminomatous germ cell tumors of the testis compared with lymph node dissection. Results of a phase-3 randomized trial showed a number of recurrences in both the patient groups. Researchers observed a higher recurrence-free survival rate in the chemotherapy group.

The article describes the case of a 61-year-old man with angioimmunoblastic T-cell lymphoma. It relates the symptoms experienced by the patient consistent with angioimmunoblastic T-cell lymphoma, including generalized lymphadenopathy, hepatosplenomegaly and weight loss. He was treated with cyclophosphamide, etoposide, procarbazine an prednisone. The patient underwent a bone marrow transplant and has been disease free.

The article discusses research on the effectiveness of a combination therapy including cyclophosphamide, mitoxantrone, vincristine, etoposide, bleomycin and prednisone plus rituximab in treating elderly patients with diffuse large B-cell lymphoma. It references a study published in a 2007 issue of "Leukemia and Lymphoma." The study revealed the effectiveness of the therapy in inducing a good remission rate with moderate toxic effects in the elderly patients.

The article focuses on the interaction of cancer drug etoposide with topoisomerase II. Etoposide is considered to be the most widely prescribed anticancer drug until the development of paclitaxel. The saturation transfer difference nuclear magnetic resonance (NMR) spectroscopy has been used in determining the points of contact and their functional relevance. Researchers found that three of etoposide's five rings interact with the enzyme.

Reports that a two-step route has been developed that can produce multikilogram quantities of the anticancer drug etoposide. Types of cancer treated by etoposide; Chemists who developed the route; Role of the monosaccharide reagent used in the process.